SCHEMBL9986207

SCHEMBL9986207

CSc1cc(O)c(SC)c(SC)c1

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9985255 0.76 MEN1 (0.38) MEN1LMNATP53GAAMAPT
SCHEMBL338483 0.75 MCL1 (0.34) MEN1LMNATP53GAAMAPT
SCHEMBL9986203 0.73
SCHEMBL21602738 0.72 SELL (0.48) MEN1LMNATP53GAAMAPT
SCHEMBL11680036 0.71 MCL1 (0.50) MEN1TP53GAAMAPTKMT2A
SCHEMBL9986069 0.70 MEN1 (0.36) MEN1LMNATP53GAAMAPT
SCHEMBL13055735 0.70 ACHE (0.52) MEN1LMNATP53GAAMAPT
SCHEMBL8794551 0.70 BACE1 (0.37) MEN1LMNATP53GAAMAPT
SCHEMBL16431900 0.70 MEN1 (0.37) MEN1LMNATP53GAAMAPT
SCHEMBL5179232 0.70 MCL1 (0.53) MEN1LMNATP53GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130635-B1 RESIN COMPOSITION, CROSS-LINKED PRODUCT, AND METHOD FOR MANUFACTURING CROSS-LINKED PRODUCT SUMITOMO CHEMICAL CO (JP) 2020-02-26 EP disclosed
US-9909002-B2 Resin composition, cross-linked product, and method for manufacturing cross-linked product SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-03-06 US disclosed
US-9695260-B2 Method for producing olefin block polymer using plurality of types of transition metal catalysts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-04 US disclosed
US-20170121516-A1 RESIN COMPOSITION, CROSS-LINKED PRODUCT, AND METHOD FOR MANUFACTURING CROSS-LINKED PRODUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-04 US disclosed
US-9593194-B2 Method for producing olefin block polymer using group 4 transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-03-14 US disclosed
EP-3130635-A1 RESIN COMPOSITION, CROSS-LINKED PRODUCT, AND METHOD FOR MANUFACTURING CROSS-LINKED PRODUCT Sumitomo Chemical Company Limited (JP) 2017-02-15 EP disclosed
US-20140275429-A1 METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING PLURALITY OF TYPES OF TRANSITION METAL CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-18 US disclosed
US-20140163173-A1 METHOD FOR PRODUCING OLEFIN BLOCK POLYMER USING GROUP 4 TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-06-12 US disclosed
US-8383848-B2 Transition metal compound and catalyst for olefin polymerization SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-02-26 US disclosed
US-20130041119-A1 OLEFIN POLYMER PRODUCING METHOD, ETHYLENE POLYMER, AND MOLD PRODUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-02-14 US disclosed
US-20110319578-A1 TRANSITION METAL COMPOUND AND CATALYST FOR OLEFIN POLYMERIZATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319578-A1 TRANSITION METAL COMPOUND AND CATALYST FOR OLEFIN POLYMERIZATION AP1M1, SOD1, YAP1 MEN1 759/4885LMNA 4321/4885TP53 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.